Duchenne Muscular Dystrophy Clinical Trial
Official title:
Performance of Upper Limb (PUL) in Duchenne Muscular Dystrophy
The literature on outcome measures assessing upper limbs in Duchenne muscular dystrophy
(DMD) is quite scanty. While there have been considerable advances for ambulant DMD boys, no
prospective study has so far been devoted to outcome measures in non ambulant patients, with
increasing complaints from families and patients. This information appears to be highly
important not only for a better understanding of the progression of the disease but also for
possible enrollment of patients in future trials.
The aim of this project is to identify outcome measures for non ambulant patients in an
Italian population of DMD patients. At least 200 non ambulant DMD boys and adults will be
included in the study. All patients will be assessed using the newly developed Performance
of Upper limb (PUL) test. This measure will be used at baseline and 6 and 12 months after
baseline. This will allow to monitor possible changes over time and the rate of changes in
patients with different level of ability and age. As part of this study the investigators
will also correlate possible changes in upper limb function with other measures of care and
function such as the EK scale.
The investigators aim to assess the suitability of the individual measures in a large number
of patients, trying to establish whether whole scales or individual items appear to be
relevant across ages and level of abilities. The investigators also aim to assess the
suitability of the selected measures in a multicentric setting and the quantity of training
required The data collected will also be analysed using Rasch analysis in order to improve
the statistical properties of the measures used.
This is a multicentric study involving a large number of patients that could not be
collected in a single Unit.
The aim of the project is to collect a large number of patients that will allow to assess
the suitability of different measures assessing upper limb function. As DMD is a relatively
rare condition, such goal can only be reached in a multicentric setting. All the
participating centres (Rome Gemelli, Messina, Rome Bambin Gesù, Pavia, Genoa, Naples, Turin,
Bologna, Padua, Milan, Bosisio Parini, Pisa) have a good record of cooperation in similar
projects having already been involved in the validation of the North Star in DMD and of the
Hammersmith Functional motor Scale for SMA.
The projects will be developed through different steps, related to different specific aims:
1. Interobserver reliability/quality and quantity of training One of the aims of the study
is to assess reliability of the selected measures in a multicentric setting and the
quantity of training required to be sure of the reliability among observers after the
training sessions. Following our experience in the training of the North Star
Ambulatory Assessment (NSAA) in the same network, the investigators have become aware
that a single training session may not be sufficient to be sure that interobserver
reliability will be maintained after the training sessions (Mazzone et al, 2009).
2. Natural history data collection The PUL will be applied to the whole cohort with
repeated assessments at 6, 12, 18 and 24 months . This will allow to monitor possible
changes over time and the rate of changes in patients with different level of ability
and age. This will also help to evaluate the responsiveness to change and the level of
sensitivity of the measure over an interval that would be useful for a study of a
putative agent that could improve muscle power.
3. Correlation with other measures Another aim of the study is to relate possible changes
in upper limb function with other measures of care and function such as the EK scale,
that provides information on aspects of function, such as transfer or self feeding that
are important in everyday life. Correlation with respiratory function will also be
performed.
4. improving statistical properties of the scales. There has been increasing evidence in
the last few years that Rasch analysis may help to improvethe statistical properties.
The data collected will offer the opportunity to perform these new psychometric
techniques.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05575648 -
Dual Task in Duchenne Muscular Dystrophy
|
N/A | |
Terminated |
NCT03907072 -
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450639 -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Active, not recruiting |
NCT04906460 -
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02500381 -
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 3 | |
Enrolling by invitation |
NCT05967351 -
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
|
Phase 3 | |
Recruiting |
NCT03067831 -
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02246478 -
A Study of TAS-205 for Duchenne Muscular Dystrophy
|
Phase 1 | |
Active, not recruiting |
NCT01772043 -
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
|
N/A | |
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT00758225 -
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
|
Phase 2 | |
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Recruiting |
NCT03513367 -
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
|
||
Recruiting |
NCT05712447 -
Duchenne Muscular Dystrophy Video Assessment Registry
|
||
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT03319030 -
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
|
||
Terminated |
NCT01753804 -
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
|
N/A | |
Completed |
NCT02530905 -
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
|
Phase 1 |